Selexipag — Discount Pricing

Other medications in Heart & Cardiovascular

• Sildenafil (PAH)
• Simvastatin
• Sotalol
• Tadalafil (PAH)
• Telmisartan
• Ticagrelor
• Torsemide
• Trandolapril

About Selexipag

Selexipag, known by its brand name Uptravi, is a vital medication for individuals managing Pulmonary Arterial Hypertension (PAH). Given its specialized nature, understanding both its function and potential costs is crucial. TheDrugClub is dedicated to helping members navigate these complexities, striving to provide access to potential savings and benefits for essential prescriptions like selexipag.

What is Selexipag and What Does It Treat?

Selexipag, marketed as Uptravi, is a prescription medication primarily used to treat Pulmonary Arterial Hypertension (PAH). PAH is a rare, progressive disease characterized by high blood pressure in the arteries leading from the heart to the lungs. This elevated pressure makes it harder for the heart to pump blood, leading to symptoms like shortness of breath, fatigue, and chest pain. Selexipag is often prescribed to slow the progression of the disease and reduce the risk of hospitalization.

How Does Selexipag Work?

Selexipag belongs to a class of drugs called prostacyclin receptor agonists. Its mechanism of action involves stimulating the prostacyclin receptor, which is found on the smooth muscle cells of blood vessels. When activated, this receptor causes the blood vessels in the lungs to relax and widen. This vasodilation reduces the pressure within the pulmonary arteries, making it easier for the heart to pump blood through the lungs. By improving blood flow and reducing strain on the heart, selexipag helps to alleviate PAH symptoms and improve overall exercise capacity.

Typical Costs of Selexipag

As a specialized medication for a rare condition, selexipag is typically very expensive. Without insurance or significant discounts, the monthly cost can range from several thousands to tens of thousands of dollars, depending on the dosage and the pharmacy. These high costs can be a significant barrier for patients, making it essential to explore all available avenues for financial assistance and savings.

How TheDrugClub Can Help with Selexipag Costs

For members of TheDrugClub, managing the cost of medications like selexipag is a primary focus. While we cannot guarantee that any specific medication will be free or fully covered, our program is designed to help members identify and potentially access various cost-saving opportunities.

1. Active-Formulary Benefits: For members with existing health insurance, TheDrugClub can assist in understanding whether selexipag is on their plan's active formulary. If it is, we can help members navigate the steps to utilize their benefits, including understanding co-pays, deductibles, and prior authorization requirements. It's important to remember that formulary coverage

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Selexipag is approved for (FDA label)

UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in adult PAH patients with WHO Functional Class II–III symptoms.

Source: Read the full FDA label on DailyMed. Label effective date: May 28, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Selexipag (FDA label)

UPTRAVI is available in the following presentations: Film-Coated Tablets 100 mcg selexipag [Light yellow tablet debossed with 1, 3 mm diameter] 150 mcg selexipag [Red tablet with no debossing, 3 mm diameter] 200 mcg selexipag [Light yellow tablet debossed with 2, 7 mm diameter] 400 mcg selexipag [Red tablet debossed with 4, 7 mm diameter] 600 mcg selexipag [Light violet tablet debossed with 6, 7 mm diameter] 800 mcg selexipag [Green tablet debossed with 8, 7 mm diameter] 1,000 mcg selexipag [Orange tablet debossed with 10, 7 mm diameter] 1,200 mcg selexipag [Dark violet tablet debossed with 12, 7 mm diameter] 1,400 mcg selexipag [Dark yellow tablet debossed with 14, 7 mm diameter] 1,600 mcg selexipag [Brown tablet debossed with 16, 7 mm diameter] UPTRAVI for Injection 1,800 mcg selexipag [Lyophilized powder white to almost white broken cake or powdered material, supplied in a 10 mL single-dose glass vial] Tablets: 100 mcg, 150 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,000 mcg, 1,200 mcg, 1,400 mcg, 1,600 mcg. ( 3 ) For Injection: 1,800 mcg of selexipag as a lyophilized powder in a single-dose vial for reconstitution and dilution. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: a7a23b87-f892-4e2c-8e2e-ebf841220f90. SPL document ID: 7c54a125-9778-41f5-b92c-181711e22e06. Label effective date: May 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Selexipag (FDA label)

Adverse reactions in adult and pediatric patients occurring more frequently (≥5%) on UPTRAVI compared to placebo are headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing. Additional adverse reaction occurring in pediatric patients more frequently (≥5%) on UPTRAVI compared to placebo is abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Actelion at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: a7a23b87-f892-4e2c-8e2e-ebf841220f90. SPL document ID: 7c54a125-9778-41f5-b92c-181711e22e06. Label effective date: May 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Selexipag (FDA label)

Hypersensitivity to the active substance or to any of the excipients. Concomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . Concomitant use with strong CYP2C8 inhibitors. ( 4 , 7.1 , 12.3 ) Hypersensitivity to the active substance or to any of the excipients. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: a7a23b87-f892-4e2c-8e2e-ebf841220f90. SPL document ID: 7c54a125-9778-41f5-b92c-181711e22e06. Label effective date: May 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.